NewswireToday - /newswire/ -
Crumlin, Antrim, United Kingdom, 2011/08/01 - Testing of oral fluid specimens is becoming increasingly popular in the workplace, prisons and in drug rehabilitation clinics - Randox.com.
Its usefulness as an aid in clinical diagnosis has been acknowledged and as a result there are many testing devices on the market for oral fluid screening. Unlike rapid tests, Randox Biochip Array Technology offers a diagnostic grade testing solution with reliable and reproducible results.
Biochip arrays offer a one-shot multiplex assay, detecting up to ninety-seven drugs and drug metabolites from an undivided oral fluid sample. Matrix dedicated kits ensure leading assay performance and excellent specificity, even at lower drug concentrations. Randox biochip arrays meet the limit of detection requirements for both the European Workplace Drug Testing Society guidelines for oral fluid testing (2010) and the Australian and New Zealand procedures for specimen collection and the detection and quantification of drugs in oral fluid AS 4760-2006 (2006).
The highly efficient Biochip arrays also provide a rapid turn around time, which is advantageous for onsite workplace drug testing. In comparison, a four-plate automated ELISA system would require thirteen times longer to process the same results. Randox recently launched a point of collection biochip analyser; the Evidence MultiStat which processes multiple results in less than twenty minutes. The Biochip platform is multi-matrix, therefore a number of sample types including oral fluid, whole blood, urine and post-mortem tissue can be run on the system. The Randox line of Evidence immunoassay analysers generate quality control data automatically with every run, ensuring that each test has been carried out successfully.
With a number of benefits to be gained from onsite testing, oral fluid will continue to be put into practice for drugs of abuse screening. As the prevalence of designer drugs and new variations of drugs enter the market, workplace drug testing is set to increase in a bid to detect and deter use. Corporations considering Workplace Drug Testing should seek to implement a drug policy and screening program in accordance with their National guidelines.
Headquartered in the United Kingdom, Randox Laboratories Ltd (randox.com) is a market leader within the in vitro diagnostics industry, manufacturing high quality diagnostic products for laboratories worldwide. Our extensive product portfolio offers complete solutions within the fields of clinical and forensic toxicology, clinical chemistry, cardiology, veterinary, drug residues, life sciences, oncology, molecular diagnostics and internal and external quality control. A continuous strategy of innovation has allowed Randox to revolutionise technology for the clinical toxicology market. Significant re-investment in Research and Development has seen the novel Biochip Array Technology adapt and evolve, with four analysers available for various settings.